EUCTR2015-005741-31-DE进行中（未招募）1 期
Fostering efficacy of anti – PD-1 – treatment: Nivolumab plus radiotherapy in advanced NSCLC - FORCE
适应症
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 入组人数
- 130
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •1. Age = 18 years at time of study entry.
- •2. ECOG performance status 0-1.
- •3. Patients with metastatic non-squamous non-small cell lung cancer after failure of platinum-based doublet chemotherapy and
- •a) no necessity of radiotherapy (group B) or
- •b) the necessity of radiotherapy of a metastatic bone lesion or soft tissue lesion (group A)
- •4. Patients must have measurable disease by CT or MRI per RECIST 1.1 criteria.
- •5. For each patient a formalin fixed, paraffin-embedded tumor tissue block (archival or recent) or a minimum of 15 unstained slides of tumor sample (2-3 µm sections; slices must be recent and collected on slides provided by the sponsor) must be available for biomarker (PD-L1) evaluation. Biopsy should be excisional, incisional or core needle. Fine needle aspiration is insufficient.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 40
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range 90
排除标准
- •1. Patients who require ongoing treatment with more than 10-mg of prednisone (or steroid equivalent, excluding inhaled or topical steroids) daily.
- •2. Prior therapy with anti-PD-1, anti-PD-L1, anti-PD-L2, anti-CD137, or anti-CTLA-4 antibody (including ipilimumab or any other antibody or drug specifically targeting T-cell co-stimulation or checkpoint pathways).
- •3. Patients with an active or recent history of a known or suspected autoimmune disease or recent history of a syndrome that required systemic corticosteroids/immunosuppressive medications EXCEPT for syndromes which would not be expected to recur in the absence of an external trigger. (Subjects with type 1 diabetes mellitus, hypothyroidism only requiring hormone replacement or skin disorders, (such as vitiligo, psoriasis, or alopecia) not requiring systemic treatment are permitted to enroll.)
- •4. Any serious or uncontrolled medical disorder or active infection that would impair the ability of the subject to receive protocol therapy
- •5. Subjects with previous malignancies (except non-melanoma skin cancers, and the following in situ cancers: bladder, gastric, colon, cervical/dysplasia, melanoma, or breast) are excluded unless a complete remission was achieved at least 2 years prior to study entry AND no additional therapy is required or anticipated to be required during the study period.
- •6. Brain metastases mandating active treatment in terms of WBI (whole brain irradiation or stereotactic brain irradiation).
- •7. Subjects with brain metastases are eligible if metastases have been treated and treatment has been completed at least 12 weeks before inclusion in this study for group B and 2 weeks for group A. Moreover, there must be no magnetic resonance imaging (MRI) evidence of progression within 28 days prior to the first dose of nivolumab administration. There must also be no requirement for immunosuppressive doses of systemic corticosteroids (> 10 mg/day prednisone equivalents) for at least 2 weeks prior to study drug administration. Patients with stable/asymptomatic brain metastases that do not require local therapy with irradiation (whole brain irradiation or stereotactic brain irradiation) can be included. In ambiguous cases, consultation with the LKP or any authorized person ist advised
- •8. Known activating EGFR mutation or a known ALK translocation.
研究者
相似试验
尚未招募
不适用
Enhancing patients defense against TB for early recovery.CTRI/2020/03/023815Department of Biotechnology
进行中（未招募）
1 期
Administration of an anti-cancer therapy, which is based on release of brakes in the natural immune response, in patients which are planned to subsequently undergo surgery for removal of their non-small cell lung cancernon-small cell lung cancer (NSCLC), resectableMedDRA version: 20.1 Level: PT Classification code 10029520 Term: Non-small cell lung cancer stage IIIA System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 20.0 Level: PT Classification code 10029518 Term: Non-small cell lung cancer stage II System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2017-000105-20-DEAIO-Studien-gGmbH30
招募中
Unknown
A Phase II study of induction PD-1 blockade (nivolumab) in patients with surgically complete resectable mismatch repair deficient endometrial cancer (NIVEC)KCT0008286Yonsei University Health System, Severance Hospital30
招募中
不适用
Prospective study of anti-PD-1 antibody therapy in advanced non-small cell lung cancer patients who previously treated with anti-PD-L1 antibodylung cancerJPRN-UMIN000033657Japanese Red Cross Medical Center30
已完成
2 期
MENIVO StudyMeningiomaJPRN-jRCT2031190074Sasaki Hikaru29